Literature DB >> 18215121

N-terminus-mediated dimerization of ROCK-I is required for RhoE binding and actin reorganization.

Ritu Garg1, Kirsi Riento, Nicholas Keep, Jonathan D H Morris, Anne J Ridley.   

Abstract

ROCK-I (Rho-associated kinase 1) is a serine/threonine kinase that can be activated by RhoA and inhibited by RhoE. ROCK-I has an N-terminal kinase domain, a central coiled-coil region and a RhoA-binding domain near the C-terminus. We have previously shown that RhoE binds to the N-terminal 420 amino acids of ROCK-I, which includes the kinase domain as well as N-terminal and C-terminal extensions. In the present study, we show that N-terminus-mediated dimerization of ROCK-I is required for RhoE binding. The central coiled-coil domain can also dimerize ROCK-I in cells, but this is insufficient in the absence of the N-terminus to allow RhoE binding. The kinase activity of ROCK-I(1-420) is required for dimerization and RhoE binding; however, inclusion of part of the coiled-coil domain compensates for lack of kinase activity, allowing RhoE to bind. N-terminus-mediated dimerization is also required for ROCK-I to induce the formation of stellate actin stress fibres in cells. These results indicate that dimerization via the N-terminus is critical for ROCK-I function in cells and for its regulation by RhoE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18215121     DOI: 10.1042/BJ20071342

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  8 in total

Review 1.  Pathophysiological Functions of Rnd3/RhoE.

Authors:  Wei Jie; Kelsey C Andrade; Xi Lin; Xiangsheng Yang; Xiaojing Yue; Jiang Chang
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 2.  Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.

Authors:  C Hahmann; T Schroeter
Journal:  Cell Mol Life Sci       Date:  2009-11-12       Impact factor: 9.261

3.  ROCK1 but not ROCK2 contributes to RhoA signaling and NMIIA-mediated contractility at the epithelial zonula adherens.

Authors:  Rashmi Priya; Xuan Liang; Jessica L Teo; Kinga Duszyc; Alpha S Yap; Guillermo A Gomez
Journal:  Mol Biol Cell       Date:  2016-11-09       Impact factor: 4.138

Review 4.  ROCK as a therapeutic target for ischemic stroke.

Authors:  Nikola Sladojevic; Brian Yu; James K Liao
Journal:  Expert Rev Neurother       Date:  2017-10-30       Impact factor: 4.618

Review 5.  The podocyte power-plant disaster and its contribution to glomerulopathy.

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Front Endocrinol (Lausanne)       Date:  2014-12-15       Impact factor: 5.555

Review 6.  Novel Insights into the Roles of Rho Kinase in Cancer.

Authors:  Lei Wei; Michelle Surma; Stephanie Shi; Nathan Lambert-Cheatham; Jianjian Shi
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-01-02       Impact factor: 4.291

7.  RhoBTB1 interacts with ROCKs and inhibits invasion.

Authors:  Raquel B Haga; Ritu Garg; Francesca Collu; Bárbara Borda D'Agua; Sofia T Menéndez; Audrey Colomba; Franca Fraternali; Anne J Ridley
Journal:  Biochem J       Date:  2019-09-13       Impact factor: 3.857

8.  Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure.

Authors:  David Komander; Ritu Garg; Paul T C Wan; Anne J Ridley; David Barford
Journal:  EMBO J       Date:  2008-10-23       Impact factor: 11.598

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.